CXCR2 Antagonist

CXCR2 Antagonists (20):

Cat. No.	Product Name	Effect	Purity

HY-16711

SB225002	Antagonist	99.87%
SB225002, a potent, selective and non-peptide CXCR2 antagonist, inhibits ¹²⁵I-IL-8 binding to CXCR2 with an IC₅₀ of 22 nM.

HY-10198

Navarixin	Antagonist	98.00%
Navarixin (SCH 527123) is a potent, allosteric and orally active antagonist of both CXCR1 and CXCR2, with K_d values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly.

HY-19855

AZD-5069	Antagonist	99.76%
AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment.

HY-101407R

Nicotinamide N-oxide (Standard)	Antagonist
Nicotinamide N-oxide (Standard) is the analytical standard of Nicotinamide N-oxide. This product is intended for research and analytical applications. Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the CXCR2 receptor.

HY-50688

SB-265610	Antagonist	≥99.0%
SB-265610 is a selective, competitive, nonpeptide and allosteric CXCR2 antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization and neutrophil chemotaxis with IC₅₀s of 3.7 nM and 70 nM, respectively.

HY-19768

Danirixin	Antagonist	98.45%
Danirixin is a selective, and reversible CXCR2 antagonist, with IC₅₀ of 12.5 nM for CXCL8.

HY-101407

Nicotinamide N-oxide	Antagonist	99.85%
Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the CXCR2 receptor.

HY-18263C

Elubrixin tosylate	Antagonist	99.78%
Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation (IC₅₀ of 260.7 nM) and shape change (IC₅₀ of 310.5 nM). Elubrixin tosylate has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation.

HY-147392

CXCR2 antagonist 8	Antagonist	99.24%
CXCR2 antagonist 8 is a potent and selective CXCR2 antagonist. CXCR2 antagonist 8 can be used for insulin resistance research.

HY-19519A

Ladarixin sodium	Antagonist	99.15%
Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthma.

HY-120878

CXCR2-IN-2	Antagonist	99.52%
CXCR2-IN-2 is a selective, brain penetrant, and orally bioavailable CXCR2 antagonist (IC₅₀=5.2 nM/1 nM in β-arrestin assay/CXCR2 Tango assay, respectively). CXCR2-IN-2 displays ~730-fold selectivity over CXCR1 and >1900-fold selectivity over all other chemokine receptors. CXCR2-IN-2 inhibits human whole blood Gro-α induced CD11b expression with an IC₅₀ of 0.04 μM.

HY-13021

SRT3190	Antagonist	99.77%
SRT3190 is an antagonist of CXCR2, used in the research of chemokine mediated diseases.

HY-119259

AZD8309	Antagonist	99.98%
AZD8309 is an orally active antagonist of CXCR2. AZD8309 has the ability to regulate the transmigration of neutrophils. AZD8309 can be used in the study of inflammatory diseases.

HY-10011

SCH 563705	Antagonist	98.20%
SCH 563705 is a potent and orally available CXCR2 and CXCR1 antagonist, with IC₅₀s of 1.3 nM, 7.3 nM and K_is of 1 and 3 nM, respectively.

HY-15462

SRT3109	Antagonist	99.82%
SRT3109 is an antagonist of CXCR2, with a pIC₅₀ of 8.2, and used in the research of chemokine mediated diseases.

HY-124056

AZ10397767	Antagonist
AZ10397767 is an orally active, selective CXCR2 receptor antagonist with an IC₅₀ of 1 nM. AZ10397767 attenuates the Oxaliplatin (HY-17371)-induced NF-κB transcriptional activity and potentiates Oxaliplatin-induced apoptosis in androgen-independent prostate cancer (AIPC) cells. AZ10397767 significantly inhibits neutrophil recruitment into tumors which then adversely affects tumor growth in vitro and in vivo.

HY-144784

CXCR2 antagonist 7	Antagonist
CXCR2 antagonist 7 (compound 19) is a potent CXCR2 antagonist. CXCR2 antagonist 7 shows potent CXCR2 binding affinity (IC₅₀=0.044 µM) and calcium mobilization (IC₅₀=0.66 µM)^{[ 1]}.

HY-144783

CXCR2 antagonist 6	Antagonist
CXCR2 antagonist 6 (compound 35c) is a potent CXCR2 antagonist. CXCR2 antagonist 6 shows potent CXCR2 binding affinity (IC₅₀=0.044 µM) and calcium mobilization (IC₅₀=0.66 µM)^{[ 1]}.

HY-144781

CXCR2 antagonist 5	Antagonist
CXCR2 antagonist 5 (compound 25) is a potent CXCR2 antagonist. CXCR2 antagonist 5 shows potent CXCR2 binding affinity (IC₅₀=0.013 µM) and calcium mobilization (IC₅₀=0.1 µM)^{[ 1]}.

HY-144780

CXCR2 antagonist 4	Antagonist
CXCR2 antagonist 4 (compound 7) is a potent CXCR2 antagonist with an IC₅₀ value of 0.13 μM. CXCR2 antagonist 4 can inhibit CXCL8-induced cytosolic calcium increase (IC₅₀ = 27 μM). CXCR2 antagonist 4 can be used for researching anticancer.

Name
Email *

	Sorry, but the email address you supplied was invalid.